http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26666596.html si-local-file:///var/storage/secattach/20260618/26666596.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26666596.html Thu, 18 Jun 2026 16:31:00 -0400 O.00066617 PSTV http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26666596.html si-local-file:///var/storage/secattach/20260618/26666596.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26666596.html Thu, 18 Jun 2026 16:31:00 -0400 O.00066617 PSTV http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26613797.html si-local-file:///var/storage/secattach/20260608/26613797.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26613797.html Mon, 08 Jun 2026 06:03:00 -0400 O.00066617 PSTV http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26613797.html si-local-file:///var/storage/secattach/20260608/26613797.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26613797.html Mon, 08 Jun 2026 06:03:00 -0400 O.00066617 PSTV http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLUS+THERAPEUTICS%2C+INC.+++For%3A+Jun+01/26611542.html si-local-file:///var/storage/secattach/20260605/26611542.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLUS+THERAPEUTICS%2C+INC.+++For%3A+Jun+01/26611542.html Fri, 05 Jun 2026 16:31:00 -0400 O.00066617 PSTV http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLUS+THERAPEUTICS%2C+INC.+++For%3A+Jun+01/26611542.html si-local-file:///var/storage/secattach/20260605/26611542.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PLUS+THERAPEUTICS%2C+INC.+++For%3A+Jun+01/26611542.html Fri, 05 Jun 2026 16:31:00 -0400 O.00066617 PSTV http://www.streetinsider.com/SEC+Filings/Form++S-3A++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26608341.html si-local-file:///var/storage/secattach/20260605/26608341.html http://www.streetinsider.com/SEC+Filings/Form++S-3A++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26608341.html Fri, 05 Jun 2026 07:31:00 -0400 O.00066617 PSTV http://www.streetinsider.com/SEC+Filings/Form++S-3A++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26608341.html si-local-file:///var/storage/secattach/20260605/26608341.html http://www.streetinsider.com/SEC+Filings/Form++S-3A++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26608341.html Fri, 05 Jun 2026 07:31:00 -0400 O.00066617 PSTV http://www.streetinsider.com/Corporate+News/CNSide+Diagnostics+receives+CAP+laboratory+accreditation/26602458.html <p>CNSide Diagnostics, a subsidiary of Plus Therapeutics (NASDAQ: PSTV), received accreditation from the College of American Pathologists for its Houston clinical laboratory. The accreditation followed an on-site inspection under the CAP Laboratory Accreditation Program.</p><p>The laboratory underwent evaluation of clinical protocols, documentation, quality control procedures, personnel qualifications, equipment, facilities, safety programs, and laboratory management. CNSide Diagnostics joins more than 8,000 CAP-accredited laboratories worldwide.</p><p>"Achieving CAP accreditation is a defining milestone for CNSide Diagnostics and an important validation of the quality, rigor, and operational discipline our team has built into every aspect of our laboratory," said Russ Bradley, President and General Manager of http://www.streetinsider.com/Corporate+News/CNSide+Diagnostics+receives+CAP+laboratory+accreditation/26602458.html Thu, 04 Jun 2026 07:30:40 -0400 PSTV http://www.streetinsider.com/Press+Releases/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html <p align="justify">HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program.</p> <p align="justify">The CAP Laboratory Accreditation Program is internationally recognized as the “gold standard” in laboratory accreditation. As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection http://www.streetinsider.com/Press+Releases/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html Thu, 04 Jun 2026 07:30:00 -0400 A.20151228 O.00050653 O.00066617 PSTV http://www.streetinsider.com/Press+Releases/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html <p align="justify">HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program.</p> <p align="justify">The CAP Laboratory Accreditation Program is internationally recognized as the “gold standard” in laboratory accreditation. As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection http://www.streetinsider.com/Press+Releases/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html Thu, 04 Jun 2026 07:30:00 -0400 A.20151228 O.00050653 O.00066617 PSTV http://www.streetinsider.com/Press+Releases/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html <p align="justify">HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program.</p> <p align="justify">The CAP Laboratory Accreditation Program is internationally recognized as the “gold standard” in laboratory accreditation. As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection http://www.streetinsider.com/Press+Releases/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html Thu, 04 Jun 2026 07:30:00 -0400 A.20151228 O.00050653 O.00066617 PSTV http://www.streetinsider.com/Press+Releases/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html <p align="justify">HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program.</p> <p align="justify">The CAP Laboratory Accreditation Program is internationally recognized as the “gold standard” in laboratory accreditation. As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection http://www.streetinsider.com/Press+Releases/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html Thu, 04 Jun 2026 07:30:00 -0400 A.20151228 O.00050653 O.00066617 PSTV http://www.streetinsider.com/Globe+Newswire/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html <p align="justify">HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program.</p> <p align="justify">The CAP Laboratory Accreditation Program is internationally recognized as the “gold standard” in laboratory accreditation. As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection http://www.streetinsider.com/Globe+Newswire/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html Thu, 04 Jun 2026 07:30:00 -0400 A.20151228 O.00050653 O.00066617 PSTV http://www.streetinsider.com/Globe+Newswire/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html <p align="justify">HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program.</p> <p align="justify">The CAP Laboratory Accreditation Program is internationally recognized as the “gold standard” in laboratory accreditation. As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection http://www.streetinsider.com/Globe+Newswire/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html Thu, 04 Jun 2026 07:30:00 -0400 A.20151228 O.00050653 O.00066617 PSTV http://www.streetinsider.com/Globe+Newswire/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html <p align="justify">HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program.</p> <p align="justify">The CAP Laboratory Accreditation Program is internationally recognized as the “gold standard” in laboratory accreditation. As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection http://www.streetinsider.com/Globe+Newswire/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html Thu, 04 Jun 2026 07:30:00 -0400 A.20151228 O.00050653 O.00066617 PSTV http://www.streetinsider.com/Globe+Newswire/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html <p align="justify">HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program.</p> <p align="justify">The CAP Laboratory Accreditation Program is internationally recognized as the “gold standard” in laboratory accreditation. As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection http://www.streetinsider.com/Globe+Newswire/Plus+Therapeutics+Announces+CAP+Accreditation+of+CNSide%C2%AE+Diagnostics+Clinical+Laboratory/26602446.html Thu, 04 Jun 2026 07:30:00 -0400 A.20151228 O.00050653 O.00066617 PSTV http://www.streetinsider.com/Equity+Offerings/Plus+Therapeutics+%28PSTV%29+files+%24100M+mixed+shelf/26586888.html <p>Plus Therapeutics (NASDAQ: PSTV) has filed $100,000,000 mixed shelf of:</p><p>Common Stock</p><p>Preferred Stock</p><p>Warrants</p><p>Debt Securities</p><p>Subscription Rights</p><p>Units</p> http://www.streetinsider.com/Equity+Offerings/Plus+Therapeutics+%28PSTV%29+files+%24100M+mixed+shelf/26586888.html Tue, 02 Jun 2026 06:10:59 -0400 PSTV http://www.streetinsider.com/Corporate+News/Plus+Therapeutics+%28PSTV%29+files+%24100M+mixed+shelf/26586888.html <p>Plus Therapeutics (NASDAQ: PSTV) has filed $100,000,000 mixed shelf of:</p><p>Common Stock</p><p>Preferred Stock</p><p>Warrants</p><p>Debt Securities</p><p>Subscription Rights</p><p>Units</p> http://www.streetinsider.com/Corporate+News/Plus+Therapeutics+%28PSTV%29+files+%24100M+mixed+shelf/26586888.html Tue, 02 Jun 2026 06:10:59 -0400 PSTV http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26586787.html si-local-file:///var/storage/secattach/20260602/26586787.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26586787.html Tue, 02 Jun 2026 06:08:00 -0400 O.00066617 PSTV http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26586787.html si-local-file:///var/storage/secattach/20260602/26586787.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++PLUS+THERAPEUTICS%2C+INC.++++++++++++++/26586787.html Tue, 02 Jun 2026 06:08:00 -0400 O.00066617 PSTV http://www.streetinsider.com/Corporate+News/Plus+CNSide+diagnostic+shows+potential+40%25+healthcare+cost+reduction/26545938.html <p>Plus Therapeutics Inc. (NASDAQ: PSTV) announced results from a health economics study indicating its CNSide cerebrospinal fluid assay may reduce healthcare costs for leptomeningeal metastases patients by approximately 33-47%.</p><p>The study, conducted with Harvard T.H. Chan School of Public Health, was presented at the ISPOR 2026 Annual Meeting in Philadelphia and received blue-ribbon recognition awarded to the top 5% of presentations. The analysis examined the economic impact of earlier detection and therapeutic management of leptomeningeal metastases using the CNSide platform.</p><p>According to the research, late-stage leptomeningeal metastases diagnosis carries substantial healthcare costs, with median inpatient admissions reaching approximately $20,000. Total monthly costs http://www.streetinsider.com/Corporate+News/Plus+CNSide+diagnostic+shows+potential+40%25+healthcare+cost+reduction/26545938.html Tue, 26 May 2026 07:32:25 -0400 PSTV http://www.streetinsider.com/Press+Releases/Plus%26apos%3B+CNSide+Diagnostic+Platform+Demonstrates+Substantial+Healthcare+Cost+Reduction+in+Patients+with+Leptomeningeal+Metastases/26545888.html <p align="center"><em>Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making </em><br/><em>reducing healthcare costs by 40%</em></p> <p align="center"><em>Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier global gathering for health economics and outcomes research</em></p> <p align="justify">HOUSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide http://www.streetinsider.com/Press+Releases/Plus%26apos%3B+CNSide+Diagnostic+Platform+Demonstrates+Substantial+Healthcare+Cost+Reduction+in+Patients+with+Leptomeningeal+Metastases/26545888.html Tue, 26 May 2026 07:30:00 -0400 A.50202511 O.00066617 O.54154398 PSTV http://www.streetinsider.com/Press+Releases/Plus%26apos%3B+CNSide+Diagnostic+Platform+Demonstrates+Substantial+Healthcare+Cost+Reduction+in+Patients+with+Leptomeningeal+Metastases/26545888.html <p align="center"><em>Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making </em><br/><em>reducing healthcare costs by 40%</em></p> <p align="center"><em>Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier global gathering for health economics and outcomes research</em></p> <p align="justify">HOUSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide http://www.streetinsider.com/Press+Releases/Plus%26apos%3B+CNSide+Diagnostic+Platform+Demonstrates+Substantial+Healthcare+Cost+Reduction+in+Patients+with+Leptomeningeal+Metastases/26545888.html Tue, 26 May 2026 07:30:00 -0400 A.50202511 O.00066617 O.54154398 PSTV http://www.streetinsider.com/Press+Releases/Plus%26apos%3B+CNSide+Diagnostic+Platform+Demonstrates+Substantial+Healthcare+Cost+Reduction+in+Patients+with+Leptomeningeal+Metastases/26545888.html <p align="center"><em>Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making </em><br/><em>reducing healthcare costs by 40%</em></p> <p align="center"><em>Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier global gathering for health economics and outcomes research</em></p> <p align="justify">HOUSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide http://www.streetinsider.com/Press+Releases/Plus%26apos%3B+CNSide+Diagnostic+Platform+Demonstrates+Substantial+Healthcare+Cost+Reduction+in+Patients+with+Leptomeningeal+Metastases/26545888.html Tue, 26 May 2026 07:30:00 -0400 A.50202511 O.00066617 O.54154398 PSTV